Corpus Intelligence IC Memo — SANTA ROSA HEALTHCARE 2026-04-26 06:42 UTC
IC Memo — SANTA ROSA HEALTHCARE
Investment Committee Memorandum | TX | 387 beds | Grade C | EBITDA uplift $38.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SANTA ROSA HEALTHCARE

CCN 450237 | BEXAR, TX | 387 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SANTA ROSA HEALTHCARE is a 387-bed suburban community hospital in BEXAR, TX with $524.1M in net patient revenue and a -9.1% operating margin. The hospital serves a payer mix of 25.2% Medicare, 1.1% Medicaid, and 73.7% commercial.

Thesis: Undervalued. Our ML models identify $38.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -9.1% to -1.7% (+736bps).

Net Revenue HCRIS$524.1M
Current EBITDA COMPUTED$-47.5M
Operating Margin COMPUTED-9.1%
Occupancy HCRIS67.2%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS17.3%
Distress Probability ML42.7%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
102
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -9.1% places it below the state median. Among 102 size-comparable peers (194-774 beds), the median margin is 4.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (194-774), prioritizing same-state peers. 102 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SANTA ROSA HEALTHCARE (Target)TX387$524.1M-9.1%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UT SOUTHWESTERN UNIVERSITY HOSTX737$2.28B-4.6%
SCOTT AND WHITE MEMORIAL HOSPITX616$1.85B-10.5%
CHILDRENS MEDICAL CENTER OF DATX377$1.56B10.3%
COOK CHILDRENS MEDICAL CENTERTX423$1.51B16.5%
CHI ST LUKES HEALTH BAYLOR MEDTX628$1.10B-9.5%
UNIVERSITY HEALTH SYSTEMTX657$1.10B-50.0%
TX HLTH HARRIS METHODIST HOSPITX653$1.03B4.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $38.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.0M+210bp18mo
Cost to Collect4.5%2.5%$10.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.4M+122bp9mo
Clean Claim Rate88.0%96.0%$335K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.0M
Cost to Collect
$10.5M
Denial Rate Reduction
$10.4M
A/R Days Reduction
$6.4M
Clean Claim Rate
$335K
Total EBITDA Uplift$38.6M
Current EBITDA$-47.5M
+ RCM Uplift+$38.6M
Pro Forma EBITDA$-8.9M
Current Margin-9.1%
Pro Forma Margin-1.7%
WC Released (1x)$20.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-73.0M$72.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-73.0M$56.1M0.00x-100.0%
Bull Case9.0x11.0x$-65.7M$159.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-65.7M$154.8M0.00x-100.0%
Bear Case11.0x10.0x$-80.4M$-96.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-80.4M$-132.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 102 hospitals with 194-774 beds
  • Same-state prioritization (n=103)
  • Comp margins: P25=-7.9% / P50=4.3% / P75=14.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.